Company Overview and News

1
Week In Review: BioSense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy

2018-10-14 seekingalpha
BioSense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs (Paris:ALNEV), a French biopharma (see story). The exercise of the option follows a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid. BioSense will make an undisclosed upfront payment plus milestones. It will also underwrite a China arm of a global Phase III IFNalpha Kinoid trial.
MVP BGNE MEIP

2
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia

2018-10-12 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Oct. 12, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced updated results from the Phase 1 clinical trial of its investigational BTK inhibitor zanubrutinib, in an oral presentation at the 10th International Workshop on Waldenström’s Macroglobulinemia (IWWM).
CELGZ CELG BGNE

3
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings

2018-10-08 globenewswire - 1
CAMBRIDGE, Mass. and BEIJING, China, Oct. 08, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced it will present data on its investigational BTK inhibitor zanubrutinib and its investigational PARP inhibitor pamiparib at two upcoming medical meetings.
CELGZ CELG BGNE

7
Cancer Investing Highlight: Another One Joins The Big Immunotherapy Contest

2018-10-02 seekingalpha
Their entry to the PD-1 space recently was approved for a new indication in the field.
AZN AZN BGNE NVS PFE SNY

2
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2018-10-01 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Oct. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on September 28, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 58,641 American Depositary Shares to 195 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan.
CELGZ CELG BGNE

5
Your Daily Pharma Scoop: Oasmia Surges, BeiGene Positive, GTx Crashes

2018-09-25 seekingalpha - 3
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space, and also provide quick commentary on other important news, and a set of selected links to major news from the day before.
OASM SUI CELG BGNE

2
BeiGene to Present at Upcoming Investor Conferences

2018-09-25 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Sept. 25, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at two upcoming investor conferences:
CELGZ CELG BGNE

1
BGNE / BeiGene, Ltd. FORM 8-K (Current Report)

2018-09-24 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
BGNE

2
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology

2018-09-22 globenewswire
BEIJING, China and CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented preliminary results from the Phase 1 trial of its investigational BTK inhibitor zanubrutinib in Chinese patients with B-cell lymphoma in an oral presentation at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China.
CELGZ CELG BGNE

2
BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology

2018-09-21 globenewswire
BEIJING, China, and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, presented clinical data on tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with lung cancers, in two oral presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China.
CELGZ CELG BGNE

2
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology

2018-09-20 globenewswire
BEIJING, China and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, presented preliminary clinical data from Chinese patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors enrolled in an ongoing Phase 1/2 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China.
CELGZ CELG BGNE

36
Top Analyst Upgrades and Downgrades: Baker Hughes, Ericsson, E*Trade, Halliburton, Nokia, SunPower, Taiwan Semi, Transocean and More

2018-09-19 247wallst - 1
Stocks were indicated to open lower on Wednesday, but this was after a solid day of gains on Tuesday. U.S. equity indexes remain very close to their all-time highs. Unfortunately, most international markets are no longer anywhere close to their highs. One issue that has to be considered is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
HAL ARPO D SPWR BBU BHGE KBR DO DRQ ERIC BHI ETFC JNPR BGNE TRI NOK MS

2
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology

2018-09-16 globenewswire
BEIJING, China and CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced four oral clinical data presentations on two of its late-stage investigational therapies, tislelizumab and zanubrutinib, at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO).
CELGZ CELG BGNE

15
2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

2018-09-10 seekingalpha - 4
Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate, two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker, our two outstanding collaborators.
VTL MNKD TSRO EXEL NVCR GERN XNET TLRY BGNE AERI WATT RDUS

 
China’s Beigene Teams up With Springworks to Target Advanced Solid Tumors

2018-09-06 biospace
Membrane-bound Ras protein in its inactive form (left) and activated form (right). Mutations in this protein can lead to solid tumors.
BGNE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 07725L102